Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：88頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014’, provides an overview of the Opioid-Induced Constipation (OIC)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014’, provides an overview of the Opioid-Induced Constipation (OIC)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Opioid-Induced Constipation (OIC) Overview 8
Therapeutics Development 9
Pipeline Products for Opioid-Induced Constipation (OIC) - Overview 9
Pipeline Products for Opioid-Induced Constipation (OIC) - Comparative Analysis 10
Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies 11
Opioid-Induced Constipation (OIC) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Opioid-Induced Constipation (OIC) - Products under Development by Companies 16
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development 17
Shionogi & Co., Ltd. 17
AstraZeneca PLC 18
Cubist Pharmaceuticals, Inc. 19
Progenics Pharmaceuticals, Inc. 20
Cosmo Pharmaceuticals S.p.A 21
Theravance, Inc. 22
Sucampo Pharmaceuticals, Inc. 23
AIKO Biotechnology, Inc. 24
Synergy Pharmaceuticals, Inc. 25
S.L.A. Pharma AG 26
Develco Pharma Schweiz AG 27
Opioid-Induced Constipation (OIC) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
naloxegol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
lubiprostone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
methylnaltrexone bromide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
methylnaltrexone bromide - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
naldemedine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
bevenopran - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
naloxone hydrochloride PR - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
methylnaltrexone bromide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
TD-1211 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
naloxone hydrochloride SR - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SP-333 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
naloxone hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
(6-beta-naltrexol + oxycodone) - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Opioid-Induced Constipation (OIC) - Recent Pipeline Updates 63
Opioid-Induced Constipation (OIC) - Dormant Projects 78
Opioid-Induced Constipation (OIC) - Discontinued Products 79
Opioid-Induced Constipation (OIC) - Product Development Milestones 80
Featured News & Press Releases 80
Nov 19, 2013: New Drug Application For Naloxegol Accepted By United States Food And Drug Administration 80
Oct 31, 2013: Synergy Pharmaceuticals Initiates Phase 2 Study of SP-333 in Patients with Opioid-Induced Constipation 80
Oct 14, 2013: AstraZeneca Announces New Safety Data For Naloxegol In Patients with Opioid-Induced Constipation 81
Oct 11, 2013: Sucampo Announces Presentation of Results on AMITIZA in Opioid-Induced Constipation at Two Upcoming Scientific Conferences 82
Oct 08, 2013: Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation 83
Oct 02, 2013: Synergy Pharmaceuticals Announces Plans to Initiate a Phase 2 Study of SP-333 for Opioid-Induced Constipation 84
Sep 27, 2013: Sucampo to Present Data on AMITIZA in Opioid-Induced Constipation at 24th Annual AAPM Meeting 84
Sep 27, 2013: Marketing Authorisation Application for naloxegol accepted by European Medicines Agency 85
Sep 04, 2013: Sucampo to Present Results From Four Phase 3 Studies of AMITIZA for Opioid-Induced Constipation at PAINWeek 2013 85
Sep 04, 2013: Salix Pharmaceuticals Previews PAINWeek Presentation 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88
List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2014 9
Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H1 2014 17
Opioid-Induced Constipation (OIC) - Pipeline by AstraZeneca PLC, H1 2014 18
Opioid-Induced Constipation (OIC) - Pipeline by Cubist Pharmaceuticals, Inc., H1 2014 19
Opioid-Induced Constipation (OIC) - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014 20
Opioid-Induced Constipation (OIC) - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2014 21
Opioid-Induced Constipation (OIC) - Pipeline by Theravance, Inc., H1 2014 22
Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2014 23
Opioid-Induced Constipation (OIC) - Pipeline by AIKO Biotechnology, Inc., H1 2014 24
Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H1 2014 25
Opioid-Induced Constipation (OIC) - Pipeline by S.L.A. Pharma AG, H1 2014 26
Opioid-Induced Constipation (OIC) - Pipeline by Develco Pharma Schweiz AG, H1 2014 27
Assessment by Monotherapy Products, H1 2014 28
Assessment by Combination Products, H1 2014 29
Number of Products by Stage and Target, H1 2014 32
Number of Products by Stage and Mechanism of Action, H1 2014 35
Number of Products by Stage and Route of Administration, H1 2014 37
Number of Products by Stage and Molecule Type, H1 2014 39
Opioid-Induced Constipation (OIC) Therapeutics - Recent Pipeline Updates, H1 2014 63
Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2014 78
Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2014 79
List of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2014 9
Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Top 10 Target, H1 2014 30
Number of Products by Stage and Top 10 Target, H1 2014 31
Number of Products by Top 10 Mechanism of Action, H1 2014 33
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 34
Number of Products by Top 10 Route of Administration, H1 2014 36
Number of Products by Stage and Top 10 Route of Administration, H1 2014 37
Number of Products by Top 10 Molecule Type, H1 2014 38
Number of Products by Stage and Top 10 Molecule Type, H1 2014 39
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Opioid-Induced Constipation (OIC) Overview 8
Therapeutics Development 9
Pipeline Products for Opioid-Induced Constipation (OIC) - Overview 9
Pipeline Products for Opioid-Induced Constipation (OIC) - Comparative Analysis 10
Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies 11
Opioid-Induced Constipation (OIC) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Opioid-Induced Constipation (OIC) - Products under Development by Companies 16
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development 17
Shionogi & Co., Ltd. 17
AstraZeneca PLC 18
Cubist Pharmaceuticals, Inc. 19
Progenics Pharmaceuticals, Inc. 20
Cosmo Pharmaceuticals S.p.A 21
Theravance, Inc. 22
Sucampo Pharmaceuticals, Inc. 23
AIKO Biotechnology, Inc. 24
Synergy Pharmaceuticals, Inc. 25
S.L.A. Pharma AG 26
Develco Pharma Schweiz AG 27
Opioid-Induced Constipation (OIC) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
naloxegol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
lubiprostone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
methylnaltrexone bromide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
methylnaltrexone bromide - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
naldemedine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
bevenopran - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
naloxone hydrochloride PR - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
methylnaltrexone bromide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
TD-1211 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
naloxone hydrochloride SR - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SP-333 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
naloxone hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
(6-beta-naltrexol + oxycodone) - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Opioid-Induced Constipation (OIC) - Recent Pipeline Updates 63
Opioid-Induced Constipation (OIC) - Dormant Projects 78
Opioid-Induced Constipation (OIC) - Discontinued Products 79
Opioid-Induced Constipation (OIC) - Product Development Milestones 80
Featured News & Press Releases 80
Nov 19, 2013: New Drug Application For Naloxegol Accepted By United States Food And Drug Administration 80
Oct 31, 2013: Synergy Pharmaceuticals Initiates Phase 2 Study of SP-333 in Patients with Opioid-Induced Constipation 80
Oct 14, 2013: AstraZeneca Announces New Safety Data For Naloxegol In Patients with Opioid-Induced Constipation 81
Oct 11, 2013: Sucampo Announces Presentation of Results on AMITIZA in Opioid-Induced Constipation at Two Upcoming Scientific Conferences 82
Oct 08, 2013: Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation 83
Oct 02, 2013: Synergy Pharmaceuticals Announces Plans to Initiate a Phase 2 Study of SP-333 for Opioid-Induced Constipation 84
Sep 27, 2013: Sucampo to Present Data on AMITIZA in Opioid-Induced Constipation at 24th Annual AAPM Meeting 84
Sep 27, 2013: Marketing Authorisation Application for naloxegol accepted by European Medicines Agency 85
Sep 04, 2013: Sucampo to Present Results From Four Phase 3 Studies of AMITIZA for Opioid-Induced Constipation at PAINWeek 2013 85
Sep 04, 2013: Salix Pharmaceuticals Previews PAINWeek Presentation 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88
List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2014 9
Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H1 2014 17
Opioid-Induced Constipation (OIC) - Pipeline by AstraZeneca PLC, H1 2014 18
Opioid-Induced Constipation (OIC) - Pipeline by Cubist Pharmaceuticals, Inc., H1 2014 19
Opioid-Induced Constipation (OIC) - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014 20
Opioid-Induced Constipation (OIC) - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2014 21
Opioid-Induced Constipation (OIC) - Pipeline by Theravance, Inc., H1 2014 22
Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2014 23
Opioid-Induced Constipation (OIC) - Pipeline by AIKO Biotechnology, Inc., H1 2014 24
Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H1 2014 25
Opioid-Induced Constipation (OIC) - Pipeline by S.L.A. Pharma AG, H1 2014 26
Opioid-Induced Constipation (OIC) - Pipeline by Develco Pharma Schweiz AG, H1 2014 27
Assessment by Monotherapy Products, H1 2014 28
Assessment by Combination Products, H1 2014 29
Number of Products by Stage and Target, H1 2014 32
Number of Products by Stage and Mechanism of Action, H1 2014 35
Number of Products by Stage and Route of Administration, H1 2014 37
Number of Products by Stage and Molecule Type, H1 2014 39
Opioid-Induced Constipation (OIC) Therapeutics - Recent Pipeline Updates, H1 2014 63
Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2014 78
Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2014 79
List of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2014 9
Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 28
Number of Products by Top 10 Target, H1 2014 30
Number of Products by Stage and Top 10 Target, H1 2014 31
Number of Products by Top 10 Mechanism of Action, H1 2014 33
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 34
Number of Products by Top 10 Route of Administration, H1 2014 36
Number of Products by Stage and Top 10 Route of Administration, H1 2014 37
Number of Products by Top 10 Molecule Type, H1 2014 38
Number of Products by Stage and Top 10 Molecule Type, H1 2014 39
